EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life

Francesca Galletta iD, Lucia Caminiti, Cecilia Lugarà, Simone Foti Randazzese iD, Paolo Barraco, Federica D'Amico iD, Pierangela Irrera, Giuseppe Crisafulli, Sara Manti iD

Journal of Personalized Medicine · 29.06.2023 · 13 (7) · 1068

DOI: 10.3390/jpm13071068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 29.06.2023. Verfasst von Francesca Galletta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98124 Messina, Italy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insufficient data are available on the long-term “real-life” safety profile of omalizumab in children. This study evaluated the long-term safety of omalizumab in a pediatric cohort with severe asthma or chronic spontaneous urticaria (CSU).

Methods

A monocentric, prospective study evaluated the long-term safety of omalizumab in patients aged 6–18 years. Each patient completed the standardized MedDRA questionnaire to identify adverse events (AEs).

Results

In total, 23 patients, median age 15 (14–18) years, affected by severe asthma (60.8%) or CSU (39.2%), treated with omalizumab for 2 (1–4) years were enrolled. The most common AEs belong to the system organ class (SOC) of general disorders and administration-site conditions (37.17%). Skin and subcutaneous tissue problems represent the second most frequently reported AEs (24.35%). Central nervous system and musculoskeletal disorders were quite frequent (15.38% and 8.97%, respectively). Other adverse events were tachycardia (5.12%), vertigo and abdominal pain (2.60% and 3.86%, respectively), and dry eye (1.3%). Only one patient reported herpes virus infection during treatment (1.3%). No cases of anaphylaxis, hemopathies, uronephropathies, respiratory, psychiatric, hepatobiliary, or oncological pathologies were reported.

Conclusions

Long-term “real-life” treatment with omalizumab in children appears well tolerated. Its safety and efficacy profile makes omalizumab an excellent alternative in severe asthma and CSU in children.

Schlagwörter

Stichwörter der Autor:innen

asthmachildrenchronic spontaneous urticariaomalizumabreal-life studysafety

Autor:innen und Institutionen

  • Pediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98124 Messina, Italy.
  • Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.

ORCID-Profile: Francesca Galletta, Simone Foti Randazzese, Federica D'Amico, Sara Manti

Zitieren

APA

Galletta, F., Caminiti, L., Lugarà, C., Foti Randazzese, S., Barraco, P., D'Amico, F., Irrera, P., Crisafulli, G., & Manti, S. (2023). Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life. Journal of Personalized Medicine, 13(7), 1068. https://doi.org/10.3390/jpm13071068

Vancouver

Galletta F, Caminiti L, Lugarà C, Foti Randazzese S, Barraco P, D'Amico F, et al. Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life. Journal of Personalized Medicine. 2023;13(7):1068. doi:10.3390/jpm13071068

BibTeX
@article{Galletta2023,
  author = {Galletta, Francesca and Caminiti, Lucia and Lugarà, Cecilia and Foti Randazzese, Simone and Barraco, Paolo and D'Amico, Federica and Irrera, Pierangela and Crisafulli, Giuseppe and Manti, Sara},
  title = {Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {7},
  pages = {1068},
  doi = {10.3390/jpm13071068}
}
Kostenlos starten →